breast cancer - HR positive | |
la/mBC - HR positive - L2 - all population | |
Immune checkpoint association | |
nivolumab plus ipilimumab | ICON |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -